Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001068197 | SCV001233293 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-08-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002418552 | SCV002727130 | uncertain significance | Cardiovascular phenotype | 2022-08-30 | criteria provided, single submitter | clinical testing | The p.G696E variant (also known as c.2087G>A), located in coding exon 16 of the JAG1 gene, results from a G to A substitution at nucleotide position 2087. The glycine at codon 696 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |